Domsicova Michaela, Kurekova Simona, Babelova Andrea, Jakic Kristina, Oravcova Iveta, Nemethova Veronika, Razga Filip, Breier Albert, Gal Miroslav, Poturnayova Alexandra
Centre of Biosciences, Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05, Bratislava, Slovakia.
Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Hněvotínska 3, 775 15, Olomouc, Czech Republic.
Biochem Biophys Rep. 2024 Aug 23;39:101816. doi: 10.1016/j.bbrep.2024.101816. eCollection 2024 Sep.
Oncological diseases represent a significant global health challenge, with high mortality rates. Early detection is crucial for effective treatment, and aptamers, which demonstrate superior specificity and stability compared to antibodies, offer a promising avenue for diagnostic advancement. This study presents the design, development and evaluation of a quartz crystal microbalance (QCM) sensor functionalized with the T2-KK1B10 aptamer for the sensitive and specific detection of Chronic Myeloid Leukemia (CML) K562 cells. The research focuses on optimizing the biorecognition layer by adjusting the aptamer conditions, demonstrating the sensor's ability to detect these CML cells with high specificity and sensitivity. The aptamer-modified QCM sensor operates on the principle of mass change detection upon binding of target cells. By employing the Langmuir isotherm model, the performance of the sensor was optimized for the capture of CML cells from biological samples with LOD of 263 K562 cells. The sensor was also successfully regenerated multiple times without sensitivity loss. Validation of the sensor's performance was conducted under controlled laboratory settings, followed by extensive testing utilizing human lyophilized plasma and clinical samples from patients. The sensor exhibited high sensitivity and specificity in the detection of CML cells within clinical specimens, thereby illustrating its potential for practical clinical deployment. This research presents a novel approach to the early diagnosis of CML, facilitating timely intervention and enhanced patient outcomes. The developed aptasensor demonstrates potential for broader application in cancer diagnostics and personalized medicine.
肿瘤疾病是一项重大的全球健康挑战，死亡率很高。早期检测对于有效治疗至关重要，与抗体相比具有卓越特异性和稳定性的适体为诊断进展提供了一条有前景的途径。本研究介绍了一种用T2-KK1B10适体功能化的石英晶体微天平（QCM）传感器的设计、开发和评估，用于灵敏且特异性地检测慢性粒细胞白血病（CML）K562细胞。该研究重点通过调整适体条件来优化生物识别层，证明了该传感器以高特异性和灵敏度检测这些CML细胞的能力。适体修饰的QCM传感器基于靶细胞结合时质量变化检测的原理工作。通过采用朗缪尔等温线模型，优化了传感器从生物样品中捕获CML细胞的性能，检测限为263个K562细胞。该传感器还成功再生了多次且无灵敏度损失。在受控实验室环境下对传感器性能进行了验证，随后利用人冻干血浆和患者临床样本进行了广泛测试。该传感器在临床标本中检测CML细胞时表现出高灵敏度和特异性，从而说明了其实际临床应用的潜力。本研究提出了一种CML早期诊断的新方法，有助于及时干预并改善患者预后。所开发的适体传感器在癌症诊断和个性化医疗中具有更广泛应用的潜力。
